Cercar

01/01/2022 Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study
Escalé-Besa A., Fuster-Casanovas A., Börve A., Yélamos O., Fustà-Novell X., Rafat M.E., Marin-Gomez F.X., Vidal-Alaball J.. Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study. Jmir Research Protocols. 2022; 11(8)DOI:10.2196/37531. PMID:. IF:(Q/D).
01/01/2022 Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey
Bechman K., Cook E.S., Dand N., Yiu Z.Z.N., Tsakok T., Meynell F., Coker B., Vincent A., Bachelez H., Barbosa I., Brown M.A., Capon F., Contreras C.R., De La Cruz C., Meglio P.D., Gisondi P., Jullien D., Kelly J., Lambert J., Lancelot C., Langan S.M., Mason K.J., McAteer H., Moorhead L., Naldi L., Norton S., Puig L., Spuls P.I., Torres T., Urmston D., Vesty A., Warren R.B., Waweru H., Weinman J., Griffiths C.E.M., Barker J.N., Smith C.H., Galloway J.B., Mahil S.K.. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2)DOI:10.1111/bjd.21042. PMID:35104366. IF:10.300(Q1/1D).
01/01/2022 Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies
Zachariae C., Mrowietz U., Strodl Andersen J., Puig L.. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4)DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2.500(Q2/5D).
01/01/2022 Leishmaniasis and anti-TNF drugs
Sánchez-Rodríguez G., Puig L.. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6)DOI:10.1016/j.piel.2021.06.020. PMID:. IF:(Q/D).
01/01/2022 International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
Van Huizen A.M., Menting S.P., Gyulai R., Iversen L., Van Der Kraaij G.E., Middelkamp-Hup M.A., Warren R.B., Spuls P.I., Schejtman A.A., Egeberg A., Firooz A., Kumar A.S., Oakley A., Foulkes A., Ramos A.M.C., Fougerousse A.-C., Carija A., Akman-Karakas A., Horváth B., Fábos B., Matlock B.H., Claréus B.W., Castro C., Ferrándiz C., Correa C.C., Marchesi C., Goujon C., Gonzalez C., Maldonado-García C., Hong C.-H., Griffiths C.E.M., Vestergaard C., Echeverría C.M., De La Cruz C., Conrad C., Törocsik D., Drvar D.L., Balak D., Jullien D., Appelen D., Kim D.H., De Jong E.M.G.J., El Gamal E., Laffitte E., Mahé E., Sonkoly E., Colombo E.P., Vilarrasa E., Willaert F., Novoa F.D., Handjani F., Valenzuela F., Vílchez-Márquez F., Gonzalez G.O., Krisztián G., Damiani G., Krnjevic-Pezic G., Pellerano G., Carretero G., Hunter H.J.A., Riad H., Oon H.H., Boonen H.P.J., Moussa I.O., García-Doval I., Csányi I., Brajac I., Turchin I., Grozdev I., Weinberg J.M., Nicolopoulos J., Wells J., Lambert J.L.W., Ingram J.R., Prinz J.C., De Souza Sittart J.A., Sanchez J.L., Hsiao J.P.-F., Castro-Ayarza J.R., Maul J.-T., Van Den Reek J.M.P.A., Trcko K., Barber K., Reich K., Gebauer K.A., Khobzei K., Maul L.V., Massari L.P., Fardet L., Le Cleach L., Misery L., Chandrashekar L., Muresanu L.I., Lecluse L., Skov L., Frez M.L., Babic L.T., Puig L., Gomez L.C., Ramam M., Dutil M., El-Sayed M.H., Olszewska M., Schram M.E., Franco M.D., Llamas-Velasco M., Gonçalo M., Velásquez-Lopera M.M., Abad M.E., De Oliveira M.D.F.S.P., Seyger M.M.B., Kaštelan M., Rademaker M., Sikora M., Lebwohl M., Wiseman M.C., Ferran M., Van Doorn M., Danespazhooh M., Bylaite-Bucinskiene M., Gooderham M.J., Polic M.V., De Rie M.A., Zheng M., Gómez-Flores M., Salleras I Redonnet M., Silverberg N.B., Doss N., Yawalkar N., Chosidow O., Zargari O., De La Cueva P., Fernandez-Peñas P., Cárdenas Rojas P.J., Gisondi P., Grewal P., Sator P., Luna P.C., Félix P.A.O., Varela P., Holló P., Cetkovska P., Calzavara-Pinton P., Ghislain P.-D., Araujo R.R., Romiti R., Kui R., Ceovic R., Vender R., Lafuente-Urrez R.F., Del-Río R., Gulin S.J., Handa S., Mahil S.K., Kolalapudi S.A., Marrón S.E., Azimi S.Z., Janmohamed S.R., Da Cruz Costa S.A., Choon S.E., Urbancek S., Ayanlowo O., Margasin S.M., Wong T.-W., Mälkönen T., Hurtová T., Reciné T.R., Huldt-Nystrøm T., Torres T., Liu T.-Y., Leonidze T., Sharma V.K., Weightman W., Gulliver W., Veldkamp W.. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5)DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10.900(Q1/1D).
01/01/2022 Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
Papp K.A., Thoning H., Gerdes S., Megna M., Brandi H., Jablonski Bernasconi M.Y., Yélamos O.. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(7)DOI:10.1080/09546634.2022.2095330. PMID:35875991. IF:2.900(Q2/4D).